Which price belongs to this edge for bmiMD NAD+ injection?

The canonical catalog records $159 a month, continuing for NAD+ injection, checked 14 September 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.

Is medication part of that number in the bmiMD figure?

The canonical bmiMD offer marks medication as included for NAD+ injection. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.

Can another route use these facts for bmiMD NAD+ injection?

This record is limited to NAD+ injection in Injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another NAD+ injection formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.

Does an empty state list prove coverage for bmiMD NAD+ injection?

Nationwide availability is not verified in the canonical record. Confirm current state eligibility before relying on the offer. The state record is only one access field. bmiMD must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific NAD+ injection prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.

Which page ranks alternatives for bmiMD NAD+ injection?

Use the canonical NAD+ injection program comparison. It reads current provider and price data from the registry and preserves the nad-injection treatment route. Compare bmiMD only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Provider treatment guide · checked 14 September 2026

bmiMD NAD+ injection

Published by Telehealth LedgerSource checked 14 September 2026Editorial policy

bmiMD lists NAD+ injection at $159 a month, continuing. Medication is included in that catalog price. Readers considering injectable NAD through bmiMD who need the injection's price basis kept separate from the nasal spray. The commercial terms were checked 14 September 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

Visit bmiMD Read the full review

bmiMD NAD+ injection treatment illustration

$159a month, continuing

Includedmedication in catalog price

Injectioncataloged format

14 September 2026commercial terms checked

Not verifiedstate-access record

The short answer for this provider-treatment pair: bmiMD NAD+ injection

Evaluate bmiMD NAD+ injection on its own format and published schedule instead of treating nasal NAD as interchangeable.

Readers considering injectable NAD through bmiMD who need the injection's price basis kept separate from the nasal spray. A fair reading keeps bmiMD's NAD+ injection listing separate from adjacent products that may use a related medication or sit in the same provider catalog.

Do not blur this product with adjacent options: NAD+ injection

NAD+ injection is cataloged as a compounded product in Injection format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this bmiMD guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.

Injection is the exact format attached to bmiMD's offer, while the canonical owner describes this comparison unit as Compounded NAD+ injection. Route matters for product identification, fulfillment, source selection, and a fair price comparison. This draft does not supply dose instructions, route conversions, or a claim that another formulation would have the same evidence, safety profile, convenience, or outcome.

The catalog-backed cost view: bmiMD

bmiMD's canonical offer lists NAD+ injection at $159 a month, continuing. The number is computed from the same registry fields used by the treatment comparison, not copied into this draft as a fixed editorial amount. That connection matters because a future catalog correction can update the displayed commercial fact without leaving this guide on a stale, contradictory figure.

The canonical offer marks medication as included in the displayed price. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For bmiMD NAD+ injection, read inclusion as one field in the offer record, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.

Billing terms to settle before payment: bmiMD NAD+ injection

The catalog has both a continuing option at $159 a month, continuing and a prepaid option at $119 a month, paying $1,428 for 12 months up front. Those are different commitments. Compare the total charged today, the renewal path, and the cancellation deadline rather than treating the lowest monthly equivalent as month to month. This is why Telehealth Ledger keeps introductory, recurring, upfront, effective-monthly, and commitment fields separate for bmiMD's NAD+ injection offer. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.

The bmiMD source for this edge was checked on 14 September 2026. Before paying for NAD+ injection, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A current catalog price cannot safely answer those policy questions unless the cited provider evidence does.

Coverage, eligibility, and fulfillment: NAD+ injection

The canonical record does not verify nationwide availability for this nad offer. An empty restriction list is not evidence of all-state coverage, so the page leaves state access unknown. The NAD+ injection access check belongs near the price because a low published figure has little decision value when bmiMD cannot serve the reader's state or the selected product cannot be fulfilled there.

For bmiMD NAD+ injection, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.

What the provider dossier adds: bmiMD

Medccm Inc dba bmiMD is recorded in the bmiMD dossier as administrator. The terms identify Medccm Inc, doing business as bmiMD, as the technology platform operator. Medccm Inc says it is not a healthcare provider and is not a HIPAA covered entity. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for NAD+ injection.

Age and U.S. customers: The terms say the Service is intended for U.S. customers and is available to individuals located in states where bmiMD offers the Service who are at least 18, or the age of majority if higher. The dossier also preserves this boundary for bmiMD's NAD+ injection decision: Sermorelin injection $139 quarterly copy versus plan picker: The injection page says "Start for $139/month. Billed quarterly, shipped monthly" while the plan picker prices the 3-month plan at $357 ($119/mo). The catalog uses the plan-picker numbers. Carry that dated limitation into checkout instead of assuming a catalog price settles operations, fulfillment, or eligibility.

Use the broader owner for ranking: NAD+ injection

The linked NAD+ injection owner is the right place to rank bmiMD beside other cataloged offers. Use the same fields for every row: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.

From this bmiMD guide, the comparison link resolves to the canonical NAD+ injection program owner, and the provider action uses the catalog's treatment-specific destination when one exists. Otherwise it uses the matching nad destination. That routing keeps the reader in the correct treatment lane and avoids sending a NAD+ injection decision to an unrelated offer.

When this offer belongs on the shortlist: bmiMD NAD+ injection

bmiMD's listing answers the basic commercial question for NAD+ injection, but it cannot answer personal eligibility, medical fit, pharmacy assignment, or an individual outcome. Those limits belong in the decision, not in fine print after it.

Readers considering injectable NAD through bmiMD who need the injection's price basis kept separate from the nasal spray. Treat the provider link as a verification step: confirm the product name, price phase, medication inclusion, state rule, pharmacy, renewal date, and refund boundary before payment.

Common questions

bmiMD NAD+ injection FAQ

Which price belongs to this edge for bmiMD NAD+ injection?: The canonical catalog records $159 a month, continuing for NAD+ injection, checked 14 September 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
Is medication part of that number in the bmiMD figure?: The canonical bmiMD offer marks medication as included for NAD+ injection. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
Can another route use these facts for bmiMD NAD+ injection?: This record is limited to NAD+ injection in Injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another NAD+ injection formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
Does an empty state list prove coverage for bmiMD NAD+ injection?: Nationwide availability is not verified in the canonical record. Confirm current state eligibility before relying on the offer. The state record is only one access field. bmiMD must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific NAD+ injection prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
Which page ranks alternatives for bmiMD NAD+ injection?: Use the canonical NAD+ injection program comparison. It reads current provider and price data from the registry and preserves the nad-injection treatment route. Compare bmiMD only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Sources and method

Telehealth Ledger checked provider pages, plan terms, and independent context on 14 September 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.